Shortly after the controversial Biogen drug for Alzheimer’s was permitted within the U.S. final yr, a pair of state Medicaid administrators tried to ring alarm bells.
In a terse letter, they implored the Biden administration to make sure Medicare covers the medication, regardless of restricted effectiveness and a $56,000 price ticket. Their reasoning was easy: If Medicare reacted to the extremely questionable approval by withholding or limiting protection, Medicaid can be left holding the proverbial bag, as a result of by legislation it should cowl medicine endorsed by the Meals and Drug Administration.
Unlock this text by subscribing to STAT+ and revel in your first 30 days free!
What’s it?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, coverage, and life science protection and evaluation.
Our award-winning workforce covers information on Wall Avenue, coverage developments in Washington, early science breakthroughs and scientific trial outcomes, and well being care disruption in Silicon Valley and past.
What’s included?
- Day by day reporting and evaluation
- Essentially the most complete business protection from a powerhouse workforce of reporters
- Subscriber-only newsletters
- Day by day newsletters to temporary you on an important business information of the day
- STAT+ Conversations
- Weekly alternatives to have interaction with our reporters and main business consultants in reside video conversations
- Unique business occasions
- Premium entry to subscriber-only networking occasions across the nation
- The very best reporters within the business
- Essentially the most trusted and well-connected newsroom within the well being care business
- And far more
- Unique interviews with business leaders, profiles, and premium instruments, like our CRISPR Trackr.
